Parting ways

While innovator drug lobbyists are desperately trying to exempt the industry from patent challenges using the inter partes review system, individual innovator companies have started to deploy IPRs against each other to clear the IP path for new drugs and biosimilars.

Sanofi and Regeneron Pharmaceuticals Inc. are using IPR to attack the Cabilly patents held by the Genentech Inc. unit of Roche and the City of Hope. The Cabilly patents, which have withstood numerous legal challenges and are slated to expire in 2018, cover methods of antibody production. ...